Contribute Try STAT+ Today

Amid a national outcry over the cost of insulin, one of the largest generic companies launched a biosimilar version at a wholesale price it claimed is 65% less than comparable treatments, although experts say the move is more likely to benefit payers than many patients.

Mylan (MYL) is marketing a long-acting version of the best-selling Lantus insulin — which the company named Semglee — for adults with Type 2 diabetes, and adults and children with Type 1 diabetes. But Mylan maintained the price for a package of 5 pens is equivalent to what Lantus sold for in 2007, and that a 10 ml vial is listed at the same price for which Lantus was sold a decade ago.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • You gotta be kidding ($98 per vial prohibitively expensive)! Do you know how much a single injection of Repatha cost?

Comments are closed.